Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Meijer

Showing results (261-270 of 282) with videos related to

Pageof 29
Sort By:
British Journal of Haematology|June 19, 2001
Molecular quantification of viral load in plasma allows for fast and accurate prediction of response to therapy of Epstein-Barr virus-associated lymphoproliferative disease after allogeneic stem cell transplantationJ W van Esser, H G Niesters, S F Thijsen, et al.
Breast Cancer Research and Treatment|July 17, 2008
Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancerMaurice P H M Jansen, Kirsten Ruigrok-Ritstier, Lambert C J Dorssers, et al.
Blood|August 9, 2001
Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell--depleted SCTJ W van Esser, B van der Holt, E Meijer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2003
Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancerEls M J J Berns, Jan G M Klijn, Maxime P Look, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2005
Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profilingMaurice P H M Jansen, John A Foekens, Iris L van Staveren, et al.
Cancer Research|April 29, 2000
Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancerE M Berns, J A Foekens, R Vossen, et al.
Cancers|May 9, 2018
The Prevalence of CD146 Expression in Breast Cancer Subtypes and Its Relation to OutcomeIngeborg E de Kruijff, Anna M Timmermans, Michael A den Bakker, et al.
The Netherlands Journal of Medicine|July 19, 2018
Clinical predictors of escalating care in hepatic and renal cyst infection in autosomal dominant polycystic kidney and liver diseaseM A Lantinga, R G L de Sévaux, T J G Gevers, et al.
International Journal of Cancer|November 16, 2005
Molecular profiling of platinum resistant ovarian cancerJozien Helleman, Maurice P H M Jansen, Paul N Span, et al.
Oncotarget|June 9, 2016
Cell-free DNA mutations as biomarkers in breast cancer patients receiving tamoxifenMaurice Phm Jansen, John Wm Martens, Jean Ca Helmijr, et al.
Pageof 29

Showing results (261-270 of 282) with videos related to

Sort By:
Pageof 29
British Journal of Haematology|June 19, 2001
Molecular quantification of viral load in plasma allows for fast and accurate prediction of response to therapy of Epstein-Barr virus-associated lymphoproliferative disease after allogeneic stem cell transplantationJ W van Esser, H G Niesters, S F Thijsen, et al.
Breast Cancer Research and Treatment|July 17, 2008
Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancerMaurice P H M Jansen, Kirsten Ruigrok-Ritstier, Lambert C J Dorssers, et al.
Blood|August 9, 2001
Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell--depleted SCTJ W van Esser, B van der Holt, E Meijer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2003
Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancerEls M J J Berns, Jan G M Klijn, Maxime P Look, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2005
Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profilingMaurice P H M Jansen, John A Foekens, Iris L van Staveren, et al.
Cancer Research|April 29, 2000
Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancerE M Berns, J A Foekens, R Vossen, et al.
Cancers|May 9, 2018
The Prevalence of CD146 Expression in Breast Cancer Subtypes and Its Relation to OutcomeIngeborg E de Kruijff, Anna M Timmermans, Michael A den Bakker, et al.
The Netherlands Journal of Medicine|July 19, 2018
Clinical predictors of escalating care in hepatic and renal cyst infection in autosomal dominant polycystic kidney and liver diseaseM A Lantinga, R G L de Sévaux, T J G Gevers, et al.
International Journal of Cancer|November 16, 2005
Molecular profiling of platinum resistant ovarian cancerJozien Helleman, Maurice P H M Jansen, Paul N Span, et al.
Oncotarget|June 9, 2016
Cell-free DNA mutations as biomarkers in breast cancer patients receiving tamoxifenMaurice Phm Jansen, John Wm Martens, Jean Ca Helmijr, et al.
Pageof 29